Advanced Search:
Equity Index Forex Crypto Commodity

ALNY - Alnylam Pharmaceuticals

$148.50  -3.59 (-2.36%)

Updated: 03:08 May 5, 2024 EST

Next Hour's AI Forecast

99.58%

Avg. Accuracy (AI)

$153.53

Next Session's AI Forecast

97.89%

Avg. Accuracy (AI)

$151.63

Next Week's AI Forecast

83.33%

Trend's Accuracy (AI)

$149.09

Alnylam Pharmaceuticals's Position Within the Biotechnology Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

ALNYLAM PHARMACEUTICALS - HISTORICAL DATA 6M

  • Last price

    $ 148.50

  • Daily change

    $ -3.59

  • Previous Close

    $ 152.09

  • Last Updated

    03:08 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.28 -0.16 -0.19 -0.09 -0.14

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.77 1.13 1.4 1.56 1.58

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
45.05% 87.69% 62.83% 29.6%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
152.78 3.63% 147.43 -1.24% 149.28 -9.24% 164.47

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.76 36.71 2.08 43.18

Alnylam Pharmaceuticals Technical Analysis News

Alnylam Pharmaceuticals

675 West Kendall Street
Henri A. Termeer Square
Cambridge, MA 02142
United States
617 551 8200
https://www.alnylam.com

Sectors: Healthcare
Industry: Biotechnology
F. Time Employees: 2100
Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 4. The pillar scores are Audit: 6; Board: 2; Shareholder Rights: 6; Compensation: 5.

ALNYLAM PHARMACEUTICALS'S HOLDERS RANK

List of holders with stock participation in Alnylam Pharmaceuticals.

Holder Rank Holder Shares Date Reported % Out Value